Personalis, Inc. Payments to Acquire Debt Securities, Available-for-sale
Personalis, Inc. (PSNL) reported Payments to Acquire Debt Securities, Available-for-sale of $94.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- Personalis, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $27.16M, a 38.31% decline year-over-year.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $67.04M, a 4.29% increase year-over-year.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $53.73M, a 19.56% increase year-over-year.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $48.15M, a 23.67% increase year-over-year.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $210.17M, a 72.69% increase from fiscal 2024.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $121.71M, a 17.09% increase from fiscal 2023.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $103.94M, a 14.44% decline from fiscal 2022.
- Personalis, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $121.49M, a 54.52% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $94.19M 10-Q · filed 2026-08-04 | $147.92M derived: sum of 3 quarters · filed 2026-08-04 | $196.07M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $67.04M 10-Q · filed 2026-05-07 | $120.77M derived: sum of 2 quarters · filed 2026-05-07 | $168.92M derived: sum of 3 quarters · filed 2026-05-07 | $212.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $53.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $101.88M derived: sum of 2 quarters · filed 2026-02-26 | $145.89M derived: sum of 3 quarters · filed 2026-08-04 | $210.17M 10-K · filed 2026-02-26 |
| 2025-09-30 | $48.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $92.17M derived: sum of 2 quarters · filed 2026-08-04 | $156.45M 10-Q · filed 2025-11-04 | $201.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $44.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $108.30M 10-Q · filed 2026-08-04 | $153.24M derived: sum of 3 quarters · filed 2026-08-04 | $192.17M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $64.28M 10-Q · filed 2026-05-07 | $109.22M derived: sum of 2 quarters · filed 2026-05-07 | $148.15M derived: sum of 3 quarters · filed 2026-05-07 | $156.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $44.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $83.87M derived: sum of 2 quarters · filed 2026-02-26 | $92.61M derived: sum of 3 quarters · filed 2026-02-26 | $121.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $38.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $47.67M derived: sum of 2 quarters · filed 2025-11-04 | $76.77M 10-Q · filed 2025-11-04 | $108.88M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $8.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $37.84M 10-Q · filed 2025-08-05 | $69.95M derived: sum of 3 quarters · filed 2025-08-05 | $117.89M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $29.09M 10-Q · filed 2025-05-06 | $61.21M derived: sum of 2 quarters · filed 2025-05-06 | $109.15M derived: sum of 3 quarters · filed 2025-05-06 | $111.51M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $32.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $80.05M derived: sum of 2 quarters · filed 2025-02-27 | $82.42M derived: sum of 3 quarters · filed 2025-02-27 | $103.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $47.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $50.30M derived: sum of 2 quarters · filed 2024-11-06 | $71.83M 10-Q · filed 2024-11-06 | $82.14M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $23.89M 10-Q · filed 2024-08-07 | $34.20M derived: sum of 3 quarters · filed 2024-08-07 | $55.32M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $21.53M 10-Q · filed 2024-05-08 | $31.84M derived: sum of 2 quarters · filed 2024-05-08 | $52.96M derived: sum of 3 quarters · filed 2024-05-08 | $83.32M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $10.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $31.43M derived: sum of 2 quarters · filed 2024-02-28 | $61.79M derived: sum of 3 quarters · filed 2024-02-28 | $121.49M 10-K · filed 2024-02-28 |
| 2022-09-30 | $21.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $51.48M derived: sum of 2 quarters · filed 2023-11-07 | $111.18M 10-Q · filed 2023-11-07 | $150.99M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $30.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $90.06M 10-Q · filed 2023-08-08 | $129.87M derived: sum of 3 quarters · filed 2024-02-28 | $150.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $59.70M 10-Q · filed 2023-05-03 | $99.51M derived: sum of 2 quarters · filed 2024-02-28 | $120.16M derived: sum of 3 quarters · filed 2024-02-28 | $212.77M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $39.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $60.46M derived: sum of 2 quarters · filed 2024-02-28 | $153.07M derived: sum of 3 quarters · filed 2024-02-28 | $267.13M 10-K · filed 2024-02-28 |
| 2021-09-30 | $20.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $113.26M derived: sum of 2 quarters · filed 2022-11-02 | $227.32M 10-Q · filed 2022-11-02 | $308.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $92.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $206.67M 10-Q · filed 2022-08-03 | $288.34M derived: sum of 3 quarters · filed 2023-02-23 | $301.34M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $114.06M 10-Q · filed 2022-05-04 | $195.73M derived: sum of 2 quarters · filed 2023-02-23 | $208.72M derived: sum of 3 quarters · filed 2023-02-23 | $248.59M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $81.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $94.67M derived: sum of 2 quarters · filed 2023-02-23 | $134.53M derived: sum of 3 quarters · filed 2023-02-23 | $161.78M 10-K · filed 2023-02-23 |
| 2020-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $52.86M derived: sum of 2 quarters · filed 2021-11-04 | $80.10M 10-Q · filed 2021-11-04 | $118.74M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $39.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $67.11M 10-Q · filed 2021-08-04 | $105.74M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $27.24M 10-Q · filed 2021-05-05 | $65.88M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $38.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $78.90M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $40.26M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |